George Raymond Zage III, a director and 10% owner of Grindr Inc. (NYSE:GRND), filed a Form 4 on September 18, 2026, disclosing the sale of 500,000 shares of common stock across two transactions on September 16 and September 17, 2026, pursuant to a Rule …
Director Alix Guerrier filed a Form 4 with the SEC on September 18, 2026, reporting the acquisition of restricted stock units in Scholastic Corporation on September 16, 2026.
Director Linda Li filed a Form 4 with the SEC on September 18, 2026, disclosing the acquisition of 3,700 restricted stock units of Scholastic Corporation on September 16, 2026.
Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp (NASDAQ:UTHR), filed a Form 4 on September 18, 2026, disclosing the exercise of stock options and sale of common stock on September 17, 2026, pursuant to a pre-arranged Rule 10b5-1 trading plan.
Paul A. Mahon, EVP and General Counsel of United Therapeutics Corp (NASDAQ:UTHR), filed a Form 4 on September 18, 2026, disclosing the exercise of 8,300 stock options and the sale of 8,300 shares of common stock on September 17, 2026, pursuant to a pre-arranged …
Steven Wu, Chief Operating Officer of American Battery Technology Co, filed a Form 4 on September 18, 2026, disclosing two transactions in the company's common stock that occurred on September 16 and September 17, 2026.
Kumar Budur, Chief Medical Officer of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), filed a Form 4 on September 18, 2026, disclosing stock option exercises and sales of common stock across three trading days from September 16 through September 18, 2026.
A Form 4 filed with the SEC on September 18, 2026, discloses that Jamie L. Reynoso, CEO of Medicare Advantage at Clover Health Investments, Corp. /DE (NASDAQ:CLOV), sold 1,921 shares of Class A Common Stock on September 17, 2026, under a pre-established Rule 10b5-1 …
An amended beneficial ownership statement for Inhibrx Biosciences, Inc. (NASDAQ:INBX) director Kristiina Vuori, MD, was filed on September 18, 2026, restating a June 4, 2026 original filing to correct the number of stock options granted due to an administrative error.
An amended ownership statement for Douglas Forsyth, a director at Inhibrx Biosciences, Inc. (NASDAQ:INBX), was filed on September 18, 2026, restating a June 4, 2026 original to correct the number of stock options reported due to an administrative error.